 |
|
Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial
Jonghoon Shin (Shin J), Jamaree Teeratakulpisarn (Teeratakulpisarn J), Thanyawee Puthanakit (Puthanakit T), Tuangtip Theerawit (Theerawit T), Ji Hwa Ryu (Ryu JH), Jinhwan Shin (Shin J), Seulgi Lee (Lee S), Hayoung Lee (Lee H), Kyungjun An (An K), Hun Kim (Kim H)
Clin Exp Pediatr. 2020;63(7):265-271. Published online 2019 Dec 6 DOI: https://doi.org/10.3345/cep.2019.01067
|
|
Citations to this article as recorded by
 Immunogenicity and seroefficacy of pneumococcal conjugate vaccines: a systematic review and network meta-analysis
Shuo Feng, Julie McLellan, Nicola Pidduck, Nia Roberts, Julian PT Higgins, Yoon Choi, Alane Izu, Mark Jit, Shabir A Madhi, Kim Mulholland, Andrew J Pollard, Simon Procter, Beth Temple, Merryn Voysey
Health Technology Assessment.2024; : 1. CrossRef Pneumococcal conjugate vaccines: choice of schedule and product development
Jin Lee
Clinical and Experimental Pediatrics.2020; 63(7): 259. CrossRef
|